A Study to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY ® Plus Standard Medical Treatment (SMT) Compared to Placebo Plus SMT to Prevent Infections in Participants With Hypogammaglobulinemia and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia
Conditions: Hypogammaglobulinemia; Bacterial Infections; B-cell Chronic Lymphocytic Leukemia Interventions: Drug: Xembify; Drug: Placebo Sponsor: Grifols Therapeutics LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials